Since the cystatin C-based eGFR (CAPA) was notably lower than the eGFR (CKD-EPI) in both groups, the question arose whether the use of the eGFR (CAPA) instead of the eGFR (CKD-EPI) would result in assignments of the patients to different CKD stages. Here, CST3 is linked to chronic kidney disease.